Cabozantinib

• Background :

  Novel inhibitor of c-met and VEGFR2 kinase activity, IC50=3.5 nm and 35 pM respectively.1 Inhibits MET-activating kinase domain mutations Y1248H, D1246N or K1262R, IC50=3.8, 11.8 and 14.6 nM respectively. In cellular assays it inhibits the following kinases: MET, VEGF2, KIT, FLT3 and AXL, IC50=7.8, 1.9, 5.0, 7.5 and 42 μM respectively.1 Eliminated approximately 80% of vasculature in spontaneous pancreatic islet tumors over 7 days in a mouse model.2 Clinically useful anticancer agent.3

• Conjugation :

  Unconjugated

• Buffer :

  White solid

• Storage Conditions :

  -20°C